Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review in SEDA Volume 40 summarizes new adverse reaction data for diuretics published in 2017, highlighting specific risks such as fractures with loop diuretics and hyperkalemia with spironolactone.

This report describes a case where travoprost treatment for open-angle glaucoma was associated with periocular hypertrichosis, hyperpigmentation, and eyelash growth, which gradually improved after discontinuation.

This article reports a case where the IOP-lowering drug bimatoprost was associated with eyelash hypertrichosis.

This study reports that periocular pigmentation may occur with the use of travoprost for treating alopecia areata of the eyelashes.

This study found that unilateral topical latanoprost use for glaucoma was associated with hypertrichosis and increased pigmentation of eyelashes in the treated eye compared to the untreated eye.

This research reports that partial orthokeratology combined with daytime spectacle correction effectively slowed myopic progression in high myopes, with a 63% reduction in axial elongation compared to spectacle use alone.

This review highlights the clinical usefulness of bimatoprost in lowering intraocular pressure for glaucoma patients and its promising results in promoting hair growth for conditions like alopecia, with research also exploring potential new applications and delivery systems.

This study found that switching patients with glaucoma or ocular hypertension from benzalkonium chloride-latanoprost to preservative-free latanoprost maintained intraocular pressure control and improved tolerability, potentially enhancing treatment adherence and quality of life.

This case report identified lash ptosis as a potential complication of latanoprost therapy in a 61-year-old man with ocular hypertension.

In this study, atropine and neosynephrine significantly reduced the incidence of intraoperative floppy iris syndrome during age-related cataract surgery in patients at high risk.

This study evaluated the stability of multiple active ingredients in TrichoSol™ for use in alopecia treatments, finding varying stability durations at room temperature—up to 180 days for some ingredients—supporting its use as a compounding vehicle in personalized therapies.

This case report observed increased eyelash growth in a trichotillomania patient using bimatoprost 0.03% solution over four months.

This review summarizes clinical trials and comparative studies showing that latanoprostene bunod 0.024% is effective and safe for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension, detailing its mechanism and side effects while considering its therapeutic role.

This study found that a single dose of TRP significantly reduced the number of UV-B-induced actinic keratosis lesions in a mouse model and was associated with improved skin histology and minimal side effects.

This review discusses the cutaneous application of bimatoprost ophthalmic solution 0.03% for enhancing upper eyelash growth and suggests it is both safe and effective; no new clinical results are reported.

This review discusses various topical medication instillation techniques for managing glaucoma but reports a lack of evidence on their effectiveness compared to usual care.

This article reviews the side effects of topical latanoprost therapy, particularly the hypertrichosis and pigmentation changes of eyelashes and nearby skin, and reports no new clinical results.

This case report highlights a rare side effect of prostaglandin analogues, detailing prostaglandin-associated periorbitopathy in three glaucoma patients treated with bimatoprost and travoprost.

In this case, intralesional cidofovir was reported to successfully treat SCC without systemic toxicity, suggesting it may be considered as an alternative to surgical excision.

In this study, a daily topical application of a 0.05% tretinoin solution effectively removed dark plugs and resolved symptoms of trichostasis spinulosa.

This paper suggests intralesional cidofovir as a potentially effective treatment for SCC with no systemic toxicity observed, but surgical excision remains the standard for its curative outcomes and thorough evaluation.

The study found that daily use of bimatoprost ophthalmic solution 0.03% for one year was effective in improving eyelash growth and patient satisfaction in both idiopathic and chemotherapy-induced hypotrichosis, with no serious drug-related adverse events reported.

In this study, daily application of bimatoprost 0.03% ophthalmic solution for 9 months significantly improved eyebrow appearance in individuals with mild to moderate eyebrow hypotrichosis, without observed side effects.

Latanoprost eye drops caused excessive hair growth and eyelash whitening in a woman.

This review describes techniques to manage intraoperative floppy iris syndrome linked to alpha-1 blocker use in cataract surgery, highlighting the need for patient disclosure of medication use but reports no new clinical results.

This study found that topical bimatoprost significantly improved eyelash growth in individuals with idiopathic and chemotherapy-induced eyelash hypotrichosis compared to a vehicle treatment.

This abstract provides summaries of multiple clinical reports on topics like macular holes with posterior uveal melanoma, hemolacria, trichotillomania management with bimatoprost, Demodex identification methods, and psychological factors in contact lens discomfort, but reports no new research findings.